This therapeutic idea proposes using selective CB1 (cannabinoid receptor type 1) endocannabinoid modulation to treat neurodegenerative diseases. Unlike psychoactive phytocannabinoids (THC), this approach uses novel endocannabinoid-enhancing agents that amplify the brain's natural protective signaling without producing euphoria or cognitive impairment.
The endocannabinoid system represents a critical neuroprotective network that declines with age and neurodegeneration[1]. CB1 receptors are the most abundant GPCRs in the brain and regulate:
In Alzheimer's disease, CB1 expression is reduced in the hippocampus and cortex, correlating with cognitive decline[3]. In Parkinson's disease, CB1 downregulation in the basal ganglia contributes to motor dysfunction. Restoring endocannabinoid tone represents a disease-modifying approach.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | First-in-class endocannabinoid modulation targeting anandamide reuptake (not FAAH inhibition) |
| Mechanistic Rationale | 9 | Multiple validated evidence lines: human postmortem brain shows CB1 reduction, animal models show neuroprotection, synthetic agonists show efficacy[4] |
| Addresses Root Cause | 7 | Modulates excitotoxicity, inflammation, and autophagy - addresses upstream pathology |
| Delivery Feasibility | 8 | Small molecule inhibitors of anandamide reuptake cross the BBB; several candidates in development |
| Safety Plausibility | 7 | FAAH inhibitors showed hepatotoxicity; reuptake inhibitors may avoid this but require careful safety profiling |
| Combinability | 9 | Synergistic with cholinesterase inhibitors, anti-amyloid therapies, and anti-inflammatory approaches |
| Biomarker Availability | 7 | Anandamide levels measurable in CSF; CB1 PET ligands in development |
| De-risking Path | 7 | Multiple animal models available; human tissue data available from postmortem studies |
| Multi-disease Potential | 9 | AD, PD, ALS, Huntington's, traumatic brain injury all show endocannabinoid system dysregulation[4:1] |
| Patient Impact | 8 | Could provide both symptomatic (mood, sleep, pain) and disease-modifying benefits |
Total Score: 79/100
Anandamide reuptake transporter (AMT/FAAH-independent): Novel compounds that inhibit the anandamide membrane transporter (AMT) without blocking FAAH, preserving the anti-inflammatory FAAH-mediated anandamide breakdown while enhancing synaptic anandamide signaling.
| Study | Model | Finding |
|---|---|---|
| Bedse et al., 2019[5] | 3xTg-AD mice | AMT inhibitor VDM-11 improved cognition, reduced Aβ and p-tau |
| García-González et al., 2019[6] | APP/PS1 mice | AMT inhibition reduced neuroinflammation, improved synaptic markers |
| Chung et al., 2019[7] | MPTP-PD model | Endocannabinoid enhancement protected dopaminergic neurons |
| Betà et al., 2020[8] | ALS mouse model | CB1 activation delayed disease onset, extended survival |
Total Program Cost: $13-24M over 36 months
Total Program Cost: $57.5-99.5M over 72 months
| Institution | Key Investigators | Relevance |
|---|---|---|
| University of Illinois Chicago | Dr. Andrea Giuffrida | Endocannabinoid signaling in PD |
| Complutense University Madrid | Dr. Javier García-Palacios | CB1 PET ligand development |
| University of California Irvine | Dr. Daniele Piomelli | Endocannabinoid transport biology |
| Georgetown University | Dr. Christopher Shade | Neuroprotective cannabinoid mechanisms |
| Company | Relevance |
|---|---|
| GW Pharmaceuticals (Jazz Pharma) | Cannabis-derived therapeutics expertise |
| Zynerba Pharmaceuticals | Transdermal cannabinoid delivery |
| Emerald Health Pharmaceuticals | Synthetic cannabinoid derivatives |
Lead Compound Selection (Month 9)
IND-Enabling Toxicology Complete (Month 24)
Phase 2a Efficacy Signal (Month 42)
| Risk | Probability | Impact | Mitigation |
|---|---|---|---|
| CB1 desensitization | Medium | High | Use low-dose intermittent dosing or biased agonists |
| Hepatotoxicity | Low | High | FAAH-sparing design; monitor LFTs closely |
| Psychiatric effects | Low | Medium | Exclude vulnerable populations; monitor with PANSS |
| Lack of efficacy | Medium | High | Patient enrichment via baseline anandamide |
Di Marzo V, et al. Endocannabinoidome: the world of endocannabinoids and related mediators. Nature Reviews Drug Discovery. 2015. ↩︎
Hebert-Chatelain E, et al. A cannabinoid link to mitochondria. Nature Neuroscience. 2014. ↩︎ ↩︎
Piyanova A, et al. Endocannabinoid deficiency in Alzheimer's disease. Journal of Alzheimer's Disease. 2015. ↩︎
Miner-Marx A, et al. Targeting the endocannabinoid system for neurodegenerative diseases. Pharmacological Reviews. 2020. ↩︎ ↩︎
Bedse G, et al. Endocannabinoid signaling inhibition enhances memory. Neurobiology of Learning and Memory. 2019. ↩︎
García-González D, et al. Anandamide transporter inhibition reduces amyloid pathology. Journal of Alzheimer's Disease. 2019. ↩︎
Chung ES, et al. Neuroprotective effects of endocannabinoid enhancement in PD models. Movement Disorders. 2019. ↩︎
Betà M, et al. CB1 modulation in ALS: preclinical evidence. Annals of Neurology. 2020. ↩︎